European Registry of Transcatheter Repair for Tricuspid Regurgitation

Last updated: March 13, 2024
Sponsor: LMU Klinikum
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Valve Disease

Heart Failure

Chest Pain

Treatment

T-TEER

Clinical Study ID

NCT06307262
EuroTR Registry
  • Ages > 18
  • All Genders

Study Summary

To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve

  • Age ≥ 18 years

Study Design

Total Participants: 3000
Treatment Group(s): 1
Primary Treatment: T-TEER
Phase:
Study Start date:
October 23, 2023
Estimated Completion Date:
December 31, 2030

Study Description

Background and Rationale:

Tricuspid regurgitation (TR) is a major health and economic burden due to high rates of heart failure hospitalizations, morbidity and mortality. Surcial treatment of TR is associated with high procedural and in-hospital mortality. Due to prohibitive surgical risk, a significant proportion of patients historically remained untreted beyond medical therapy. Transcatheter tricuspid valve (TV) repair and replacement techniques (TTVT) now offer a new treatment perspective for these patients. The EuroTR registry aims at optimizing patient selection prior to TTVT and thus treatment quality by collecting respective data in a real-world setting.

Objectives:

To investigate clinical and survival outcome following transcatheter tricuspid valve repair or replacement.

Connect with a study center

  • LMU Klinikum

    Munich, Bavaria 81377
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.